F. C. da Silva

Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?

T. Roumeguère, A. Merseburger, A. Alcaraz, 2014, World Journal of Urology.

Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients

F. Hamdy, D. Chopin, P. Teillac, 1996, The Prostate.

Updated concepts and treatment of carcinoma in situ.

D. Lamm, F. Mostofi, I. Sesterhenn, 1998, Urologic oncology.

Stauffer's syndrome: A comprehensive review and proposed updated diagnostic criteria.

F. D. da Silva, Mário Fontes-Sousa, H. Magalhães, 2018, Urologic oncology.

Trypanosoma cruzi: insights into naphthoquinone effects on growth and proteinase activity.

M. G. Albuquerque, H. Castro, C. R. Rodrigues, 2011, Experimental parasitology.

[Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study].

P. Boyle, F. Hamdy, F. Debruyne, 2002, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

4'-epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer.

F. D. da Silva, A. Santos, F. Ferrito, 1992, European urology.

Quality of life in prostatic carcinoma.

F. D. da Silva, F. C. da Silva, 1993, European urology.

Dithiothreitol-based protein equalization technology to unravel biomarkers for bladder cancer.

H. López-Fernández, H. Santos, J. Capelo, 2018, Talanta.